Trial Profile

A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liraglutide (Primary)
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms ADJUNCT TWO
Sponsors Novo Nordisk

Most Recent Events

01 Dec 2021 Results of post-hoc analysis of two studies (ADJUNCT ONE and ADJUNCT TWO) assessing 26 weeks of liraglutide treatment in type 1 diabetes (T1D), published in the Diabetes, Obesity and Metabolism.
29 Jun 2021 Results of randomized controlled phase 3 trials (ADJUNCT ONE (NCT01836523) and TWO (NCT02098395)), presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com